Results 201 to 210 of about 6,366 (244)
Some of the next articles are maybe not open access.
Pediatric Cardiology, 1982
Life-threatening irreversible cardiomyopathy is a major complication of anthracycline therapy, particularly in the pediatric population. The pediatric cardiologist, in concert with the primary oncologist, should therefore play a major role in the care of patients receiving these agents and in clinical trials involving their use.
N L, Kobrinsky, N K, Ramsay, W, Krivit
openaire +2 more sources
Life-threatening irreversible cardiomyopathy is a major complication of anthracycline therapy, particularly in the pediatric population. The pediatric cardiologist, in concert with the primary oncologist, should therefore play a major role in the care of patients receiving these agents and in clinical trials involving their use.
N L, Kobrinsky, N K, Ramsay, W, Krivit
openaire +2 more sources
Cardiotoxicity of Anthracyclines
Cardiology ClinicsAnthracycline chemotherapy is associated with cardiotoxicity, predominantly manifesting as left ventricular systolic dysfunction within the first year of treatment. Early detection is possible through biomarkers and cardiovascular imaging before clinical symptoms develop.
Elizabeth, Balough +3 more
openaire +2 more sources
ANTHRACYCLINE CARDIOTOXICITY IN CHILDHOOD
Pediatric Hematology and Oncology, 2008Over the last 40 years, a significant advance has been made in the treatment of childhood and adult cancers. However, the increase of the survival rate points out medium- and long-term adverse effects that constitute a serious limitation for the quality of life in adults survived from a childhood cancer.
Ruggiero, Antonio +6 more
openaire +2 more sources
2007
The clinical use of doxorubicin and other quinone-hydroquinone anticancer anthracyclines is limitedby a dose-related cardiotoxicity. Here, we review the correlation of cardiotoxicity of doxorubicinwith its peak plasma concentration and diffusion in the heart, followed by reductive bioactivation or oxidativeinactivation.
Pierantonio, Menna +3 more
openaire +2 more sources
The clinical use of doxorubicin and other quinone-hydroquinone anticancer anthracyclines is limitedby a dose-related cardiotoxicity. Here, we review the correlation of cardiotoxicity of doxorubicinwith its peak plasma concentration and diffusion in the heart, followed by reductive bioactivation or oxidativeinactivation.
Pierantonio, Menna +3 more
openaire +2 more sources
[Anthracycline cardiotoxicity].
La Clinica terapeutica, 2003To provide specialists and general practitioners with a review of the more recent data about anthracycline-induced cardiotoxicity and diagnostic methods utilized to reveal it.Reviewers identified studies concerning anthracycline cardiotoxicity, with special emphasis to those dealing with its pathogenesis and tools utilized for diagnosing it, by ...
FINOLEZZI E +3 more
openaire +2 more sources
Cancer chemotherapy and biological response modifiers, 1990
After twenty years, understanding the mechanisms of tumor cells kill by anthracyclines still remains an active area of research. Of many mechanisms described for this class of drugs, efforts in the last year have focused on defining the role of free radical formation, topoisomerase II-induced DNA breakage, and P-170-dependent cellular accumulation of ...
B K, Sinha, P M, Politi
openaire +6 more sources
After twenty years, understanding the mechanisms of tumor cells kill by anthracyclines still remains an active area of research. Of many mechanisms described for this class of drugs, efforts in the last year have focused on defining the role of free radical formation, topoisomerase II-induced DNA breakage, and P-170-dependent cellular accumulation of ...
B K, Sinha, P M, Politi
openaire +6 more sources
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Molecular Aspects of Medicine, 2023Roberto Mattioli +2 more
exaly